Study evaluating dosimetry, randomized dose optimization, dose escalation, and efficacy of Ac-225 rosopatamab tetraxetan in participants with PSMA PET-positive castration-resistant prostate cancer. Here, FOLH1 is linked to prostate carcinoma.